Uncategorized

xCures’ technology harnesses real-time patient data and makes it accessible for scientific exploration and to improve patient options.

Today, xCures and the Diffuse Intrinsic Pontine Glioma (DIPG) / Diffuse Midline Glioma (DMG) Research Funding Alliance (DDRFA) are proud to announce their partnership, a collaboration focused on leveraging real-time patient data to drive forward DMG (including DIPG) scientific study and patient care options.

Through this collaboration, xCures aims to streamline DMG research and enhance patient care by centralizing the collection and analysis of anonymized DMG patient data. By enhancing scientific discovery while upholding patients´ and doctors´ stringent privacy and security standards, this partnership will significantly advance patient-driven research and treatment options.

“We’re incredibly excited to join forces with xCures,” said Lisa Ward, coordinator for DDRFA. “Through this collaboration, we’re leveraging cutting-edge technology to elevate DIPG and DMG research. Our vision is to learn from every patient in real-time, aggregate this vital data, and make it accessible for further scientific exploration. Equally as important, is to structure data to be widely accessible to academic researchers and industry poised to bring discoveries in this nearly universally fatal childhood cancer.”

xCures, renowned for its technology solutions in oncological clinical research, will provide a secure platform for data gathering and analysis. Their unique ‘Privacy by Design’ approach ensures patient data privacy, a crucial element of this partnership, and thus facilitates the creation of an extensive, dynamic dataset that reflects the real-world experiences of DMG patients. Moreover, the dataset’s continuous updates will offer researchers timely insights into treatment responses, symptom progression, and patient outcomes.

“Collaborating with DDRFA will permit us to apply our technology towards a critically important cause,” commented Mika Newton, the CEO of xCures. “We believe this partnership will have a crucial role in advancing DIPG and DMG research, and ultimately improving patient care.”

By fostering a more profound understanding of DIPG, xCures and DDRFA strive to spark scientific breakthroughs and inform treatment decisions, significantly improving the prognosis for patients living with this devastating disease.

Patients and caregivers that want to help and leverage the power of this collaboration are encouraged to visit www.xcures.com/dmg

About DDRFA
DDRFA is a leading not-for-profit alliance of over 60 separate foundations and funds dedicated to the research and advocacy of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffused Midline Glioma (DMG). Its mission is to drive forward scientific understanding and treatment options for DIPG and DMG through fostering collaborative research efforts and increasing public awareness. DDRFA is coordinated by Tough2gether Foundation. Many of its member organizations are founded by families in memory of children lost to DIPG and DMG. Together the members fund cutting-edge research because they know well that young lives depend on them. For more information, visit www.ddrfa.org

About xCures
xCures Inc. operates an AI-assisted platform that offers patients and oncologists access to all their medical records, irrespective of where they were treated, an always up-to-date comprehensive Care Summary, and a Treatment Options Report. This service is free and designed to help all cancer patients get the right therapy at the right time.

The fully longitudinal (unstructured) patient clinical data is aggregated and organized for use by life sciences professionals in studies and decentralized trials. For more information, visit www.xcures.com

CureMatch will leverage the xCures technology that automatically creates a comprehensive outline of a cancer patient’s medical history in order to improve treatment recommendations.

CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a partnership with xCures, Inc., to connect cancer patients and physicians with optimal investigational or approved therapies. CureMatch will leverage the xCures technology platform to create a comprehensive outline of a cancer patient’s medical history and further enhance its precision cancer treatment recommendation capabilities.

CureMatch analyzes an individual patient’s genetic sequencing report to determine which drug combinations, out of the millions possible, could most effectively treat their cancer. It then provides oncologists with clear, accessible, predictive treatment analysis in an easy-to-read report that equips them with actionable knowledge tailored for each unique case. With xCures, cancer patients get immediate access to their care summary and all of their medical data in one easy-to-access place, greatly facilitating the finding of promising treatment options, even as they seek second opinions and try new therapies.

The collaboration between CureMatch and xCures will give oncologists clear, comprehensive access to patient records and past treatments, enabling them to make more informed recommendations for combination precision cancer treatments based on the CureMatch report.

“The collaboration between xCures and CureMatch brings together two leading companies at the forefront of digital healthcare innovation,” said Mika Newton, CEO of xCures. “By combining our strengths, we are confident that we can accelerate the adoption of precision oncology and improve outcomes for cancer patients globally.”

“This partnership represents a significant step forward in harnessing the power of AI technology to optimize cancer care,” said Navid Alipour, CEO of CureMatch. “By combining xCures’ patient medical history platform and our treatment-matching algorithm, we can make the process of obtaining genetically tailored, precision cancer therapies a reality for more patients.”

About CureMatch®

CureMatch is a leader in precision medicine digital solutions. Created on the belief that oncologists everywhere should benefit from world-class research, the CureMatch Decision Support System helps guide oncologists in the selection of cancer drugs that are customized for individual patients based on the molecular profile of their tumor, allowing each oncologist to become an expert in personalized medicine for better patient outcomes. www.CureMatch.com

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

For more information, contact info@xcures.com or visit our homepage.

Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations. 

[Oakland, CA, May 26, 2023] – xCures, a healthcare technology company, is pleased to announce its participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, to be held from June 02 – 06, 2023, at McCormick Place, Chicago, IL USA.  

The two abstracts accepted showcase the capabilities of its real-time clinical data platform to support patient care. The abstracts illustrate the platform´s enhanced longitudinal nationwide data beyond existing traditional retrospective real-world data (RWD) and how its platform can prospectively track clinical outcomes for (rare) cancer patient populations and structure clinical data for decision support.

“Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled capacity to extract insights from patient medical records,” said Tim Stuhlmiller, Vice President of Scientific and Medical Affairs at xCures, “these abstracts showcase our ability to utilize real-world data to improve patient care today, rather than 2-5 years from now.”

The xCures data platform, powered by a connection to the health information exchange and structured FHIR and CCDA data direct from institutional EMRs, has enabled a nationwide analysis of glioblastoma therapeutic combinations.

Under the guidance of Dr. Michael Castro of the Beverly Hills Cancer Center, a potentially practice-changing detrimental effect of proton pump inhibitors in glioblastoma was unveiled. This data is critical since up to 60% of brain cancer patients are prescribed these drugs, which could easily be exchanged for drugs with a different mechanism of action.

In a second abstract, xCures supports Dr. Paul Kent and the FibroFighters advocacy group to implement a multidisciplinary, international tumor board for fibrolamellar carcinoma, a rare adolescent and young adult cancer.

This tumor board is one of the world´s few international virtual tumor boards and the first ever for fibrolamellar carcinoma, offering patients a free consultation from leading experts. The xCures outcomes database provides actionable clinical data to guide decision-making in the tumor board. In addition, the platform collects outcomes prospectively to close the learning loop and improve future recommendations of the board.

Attendees of the ASCO Annual Meeting are encouraged to find Tim Stuhlmiller, Mark Shapiro, and Max Goldstein from xCures, who can provide in-depth insights, discuss potential collaborations, and showcase case studies from the platform´s implementation.

The abstracts presented:

Use of proton pump inhibitors (PPI) in glioblastoma (GBM) and relationship to overall survival in a national real-world evidence (RWE) database.

Authors: Michael Castro, Jameson Quinn, Asher Wasserman, Mark Shapiro, Timothy Stuhlmiller, Santosh Kesari

https://meetings.asco.org/abstracts-presentations/223217

and,

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.

Authors: Paul Kent, Jordan Tasse, Erik Schadde, Tomoaki Kato, Abhinav Humar, Oliver Fisher, Matthew Dixon, Darrell Yamashiro, Albert Cornelius, Nelson Royall, Thomas Kim, Julie Friedland, Timothy Stuhlmiller, Alaa Awawda, Alanis Sabates, Mark Shapiro, Jessica Ellison, Tom Stockwell

https://meetings.asco.org/abstracts-presentations/224077

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform´s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

For more information, contact info@xcures.com or visit http://www.xcures.com.

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to better inform the treatment of Genome Medical patients.

Genome Medical’s national reach and industry-leading genetic counseling services deliver critical insights and care to patients as they understand the risk factors and genetic implications of their conditions.

“Together, we are delivering the knowledge and data that is vital for precision medicine,” said Mika Newton, CEO of xCures. “Our real-time clinical data offers unique insights for patients and providers in their fight against cancer.”

“We look forward to collaborating with xCures to deliver an enhanced level of care to our patients and with an even more complete view of the patient’s health background,” said Jill Davies, CEO of Genome Medical. “This collaboration will have a great impact on the patients we serve, with the potential for an even greater impact on population health through enhanced research for oncology and other inherited diseases.”

Incorporating xCures’ real-world clinical data into the comprehensive Genome Medical genetic counseling sessions is another example of both companies’ mission to help integrate powerful genetic insights into a patient’s health journey.  It brings to life the promise of genomic medicine, making genetic information clinically actionable for patients and their providers while supporting providers in their efforts to deliver genetic services at-scale.

The companies will also collaborate with researchers to use the aggregated knowledge gathered from this initiative to further research and treatment that has the potential to improve care and outcomes across care settings. With this exciting new collaboration, Genome Medical and xCures are revolutionizing patient care and shaping the future of connected health.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com.

About Genome Medical

Genome Medical, the leading telegenetics care delivery company, is making genetic care accessible and actionable for patients through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, Genome Medical expands the reach and impact of genomic medicine. The company helps its partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre and post-test genetic counseling through its team of expert genetic counselors and personalized care plans. Headquartered in South San Francisco, Genome Medical has been honored as “The Best Digital Health Company to Work For” by Rock Health and the “Top 50 in Digital Health” by Fenwick & West and Goldman Sachs. To learn more, visit genomemedical.com and follow @GenomeMed.